SCHEMBL14868103

SCHEMBL14868103

O=c1c2ccccc2nc2n(-c3nc(-c4cccc(-c5ccccc5)c4)cc(-c4cccc(-c5ccccc5)c4)n3)c3ccccc3n12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ ADORA2B P29275 2/20 0.38
▸ ADORA1 P30542 2/20 0.38
▸ PDE10A Q9Y233 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ DHODH Q02127 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14868102 0.93 KDM4E (0.42) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL17874518 0.89 SMN1; SMN2 (0.40) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL12071444 0.84 ADORA2B (0.49) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL12073550 0.83 PDE10A (0.48) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL12073553 0.83 KMT2A (0.43) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL12073545 0.83 KMT2A (0.50) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL12073112 0.83 KDM4E (0.44) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL12071648 0.82 ADORA2B (0.48) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL12071404 0.81 ADORA2B (0.47) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E
SCHEMBL12071458 0.81 ADORA2B (0.50) SMN1; SMN2NPC1RAB9AHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160260911-A1 MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-09-08 — — US disclosed
US-20160260911-A1 MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-09-08 — — US disclosed
US-20130092922-A1 MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2013-04-18 — — US disclosed
US-20130092922-A1 MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2013-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160260911-A1 MATERIALS FOR ELECTRONIC DEVICES SCO2, AOC2, HCN2 SMN1; SMN2 4065/4885NPC1 2473/4885RAB9A 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback